Insights into Early Stage of Antibiotic Development in Small and Medium-Sized Enterprises: A Survey of Targets, Costs, and Durations

Journal of Pharmaceutical Policy and Practice (2018) 11:8

Boston Univ. School of Law, Public Law Research Paper

12 Pages Posted: 27 Sep 2019

See all articles by Christine Ardal

Christine Ardal

Norwegian Institute of Public Health

Enrico Baraldi

Uppsala University

Ursula Theuretzbacher

Center for Anti-Infective Agents

Kevin Outterson

Boston University School of Law

Francesco Ciabuschi

Uppsala University

Jens Plahte

Norwegian Institute of Public Health

John-Arne Røttingen

Norwegian Knowledge Center for the Health Services

Date Written: 2018

Abstract

Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other drugs. This paper attempts to gather a better understanding of SMEs’ targets, costs, and durations related to discovery and early phase development of antibacterial therapies.

Suggested Citation

Ardal, Christine and Baraldi, Enrico and Theuretzbacher, Ursula and Outterson, Kevin and Ciabuschi, Francesco and Plahte, Jens and Røttingen, John-Arne, Insights into Early Stage of Antibiotic Development in Small and Medium-Sized Enterprises: A Survey of Targets, Costs, and Durations (2018). Journal of Pharmaceutical Policy and Practice (2018) 11:8 ; Boston Univ. School of Law, Public Law Research Paper. Available at SSRN: https://ssrn.com/abstract=3459710

Christine Ardal

Norwegian Institute of Public Health ( email )

PO Box 4404
Nydalen, N-0403
Oslo
Norway

Enrico Baraldi

Uppsala University ( email )

Box 513
Uppsala, 751 20
Sweden

Ursula Theuretzbacher

Center for Anti-Infective Agents

Austria

Kevin Outterson (Contact Author)

Boston University School of Law ( email )

765 Commonwealth Avenue
Boston, MA 02215
United States

Francesco Ciabuschi

Uppsala University ( email )

Box 513
Uppsala, 751 20
Sweden

Jens Plahte

Norwegian Institute of Public Health ( email )

PO Box 4404
Nydalen, N-0403
Oslo
Norway

John-Arne Røttingen

Norwegian Knowledge Center for the Health Services ( email )

Norway

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
5
Abstract Views
104
PlumX Metrics